1
0
0
News
Cetuximab s irinotecanem, fluorouracilem a leucovorinem ...Tribune.cz
www.tribune.cz
... Angela Zubel, Ilhan Celik, Philippe Rougier a Fortunato Ciardiello Vyšlo v titulu Journal of Clinical Oncology. Cetuximab s irinotecanem, fluorouracilem a ...
Debiopharm renforce sa présence en immuno-oncologie par le lancement...
www.finanzen.ch
Premier patient recruté dans l'étude SMARTPLUS-106, chez des patients atteints de tumeurs solides pour lesquels le traitement anti-PD-1 et anti-PD...
Debiopharm Announces Launch Of The Phase 1/2 GaLuCi ...FirstWord Pharma
firstwordpharma.com
" explained Angela Zubel, Chief Development Officer at Debiopharm. "We always have immense gratitude for our patients who participate in first time in human ...
Debiopharm begins enrolment in CATRIPCA trialClinical Trials Arena
www.clinicaltrialsarena.com
— Debiopharm chief development officer Dr Angela Zubel said: “This study is the third of a series of immuno-oncology studies investigating the ...
Netzwerk-Profile
LinkedIn: Angela Zubel | LinkedIn
Angela Zubels berufliches Profil anzeigen LinkedIn ist das weltweit größte professionelle Netzwerk, das Fach- und Führungskräften wie Angela Zubel dabei hilft ...
LinkedIn: Angela Zubel | LinkedIn
Sehen Sie sich das berufliche Profil von Angela Zubel (Deutschland) auf LinkedIn an. LinkedIn ist das weltweit größte professionelle Netzwerk, das Fach- und ...
LinkedIn: Angela Zubel – Chief Development Officer – Debiopharm International ...
Sehen Sie sich das Profil von Angela Zubel auf LinkedIn an, dem weltweit größten beruflichen Netzwerk. 4 Jobs sind im Profil von Angela Zubel aufgelistet.
Interessen
Debiopharm Expands its Immuno-Oncology Development Program for Debio...
markets.businessinsider.com
Angela Zubel, Chief Development Officer, Debiopharm International SA. About Debio Debio is a IAPs inhibitor with a dual mode of ...
Wyniki wyszukiwania
expertus.bm.cm-uj.krakow.pl
Autorzy: Józef Krzysiek, Tomasz Milewicz, Katarzyna Augustowska, Krystyna Sztefko, Janusz Ryś, Angela Zubel, Kazimierz Pityński, Piotr Jaszczyński, Krzysztof Herman, Antoni Basta, Jerzy Stachura, Ewa Ł. Gregoraszczuk. Tytuł oryginału: The impact of progesterone on simultaneous, local secretion of IGFBP-3 and IGF-I ...
Debio and high-dose cisplatin chemoradiotherapy in ...The Lancet
www.thelancet.com
... Angela Zubel, MD, Claudio Zanna, MD, Silvano Brienza, MD, Philippa Crompton, MSc, Elisabeth Rouits, PharmD, Kathrin Gollmer, PhD, Sergio Szyldergemajn, MD ...
Induction chemotherapy followed by concurrent chemoradiotherapy...
www.em-consulte.com
Faiz Niazi, Simon Wandel, Malte Peters, Angela Zubel, Reinhard Dummer.
Management & Beteiligungen
Angela Zubel in Arzier-Le Muids - Auskünfte | Moneyhousewww.moneyhouse.ch › Startseite › Personen
www.moneyhouse.ch
Angela Zubel in Arzier-Le Muids aus Deutschland ✓ Verbunden mit 1 Firma ✓ keine Beteiligungen ✓ Debiopharm International SA.
Angela Zubel à Arzier-Le Muids - RenseignementsMoneyhouse
www.moneyhouse.ch
Angela Zubel à Arzier-Le Muids de Allemagne ✓ Associé-e à 1 entreprise ✓ 0 participation ✓ Debiopharm International SA.
Debiopharm International SA in LausanneMoneyhouse
www.moneyhouse.ch
Angela Zubel, Pierre Jullian-Gaufres, Frédéric Lévy, Thierry Mauvernay. Quelle: SHAB · Komplettes Management ansehen. Netzwerk. Netzwerk im Detail ansehen.
Business-Profile
ANGELA ZUBEL - Chief Development Officer ...Crunchbase
www.crunchbase.com
Angela Zubel is the Chief Development Officer at Debiopharm International SA.Angela Zubel attended Heidelberg University.
Biographie de Angela ZubelThe Official Board
www.theofficialboard.fr
— Angela Zubel est actuellement Chief Development Officer chez Debiopharm International. Chez Debiopharm International, Angela Zubel a
Firmen-Mitarbeiter
LeadershipNovadiscovery
www.novadiscovery.com
Angela Zubel. Chief Development Officer at Debiopharm International - Board Observer. Read biography.
Private Homepages
Caris Life Sciences Partners with Debiopharm International ...Caris Life Sciences
www.carislifesciences.com
— ... Angela Zubel, Chief Development Officer at Debiopharm International SA. “We believe that a whole transcriptome assay is particularly ...
Bücher
heiBIB: Zubel, Angela
katalog.ub.uni-heidelberg.de
ADAM9 expression in CIN lesions and cervical cancer / vorgelegt von Angela Zubel, ...
Estrogen Receptor Alpha and ADAM9 Expression in CIN Lesions and...
books.google.de
Angela Zubel pages. 0 Reviewshttp://books.google.com/books/about/Estrogen_Receptor_Alpha_and_ADAM9_Expres.html?id=01TNYgEACAAJ ...
Dokumente zum Namen
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor...
www.scienceopen.com
Authors: Philippe L Bedard, Josep Tabernero, Filip Janku, Zev A Wainberg, Luis Paz-Ares, Johan Vansteenkiste, Eric Van Cutsem, José Pérez-García, Anastasios Stathis, Carolyn D Britten, Ngocdiep Le, Kirsten Carter, David Demanse, Denes Csonka, Malte Peters, Angela Zubel, Heidi Nauwelaerts, Cristiana Sessa.
Abstract - ASCO Annual MeetingAmerican Society of Clinical Oncology
meetings.asco.org
... Angela Zubel, Josep Tabernero, Keith Flaherty, David Michael Hyman. Organizations. Dana Farber Cancer Institute, Boston, MA, Memorial Sloan Kettering Cancer ...
Fluorouracil, Leucovorin, and Oxaliplatin With and Without FormSusformsus.datasus.gov.br/novoimgarq _ pdf
formsus.datasus.gov.br
... Serban Donea, Heinz Ludwig, Gunter Schuch, Christopher Stroh, Anja H. Loos,. Angela Zubel, and Piotr Koralewski. From the University Hospital, Hamburg-.
Efficacy and safety of oral MEK162 in patients with locally ...Semantic Scholar
pdfs.semanticscholar.org
von PA Ascierto · Zitiert von: 93 — Angela Zubel, Faiz Niazi, Simon Wandel, Reinhard Dummer. *National Cancer Institute, Naples. Italy. Page 2. Disclosures. •. Employment or Leadership Position ...
Wissenschaftliche Veröffentlichungen
MEK162 for patients with advanced melanoma harbouring ...ScienceDirect
www.sciencedirect.com
von PA Ascierto · · Zitiert von: 743 — , Faiz Niazi MPharm j , Simon Wandel PhD j , Malte Peters MD j , Angela Zubel MD j , Prof Reinhard Dummer MD k. Show more. Add to Mendeley. Share. Cite.
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin ...TU Dresden
fis.tu-dresden.de
— Angela Zubel - (Author); Ilhan Celik - (Author); Philippe Rougier - (Author); Fortunato Ciardiello - (Author). Abstract. PURPOSE: The addition ...
Angela Zubel – ScienceOpen
www.scienceopen.com
cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) ...
EPIC: phase III trial of cetuximab plus irinotecan after ...Hal-Inria
inria.hal.science
von AF Sobrero · · Zitiert von: — ... Angela Zubel , Christiane Langer , Justin Kopit , Howard A. Burris. Afficher plus de détails. 1 RIGHT - Interactions hôte-greffon-tumeur, ingénierie ...
Veröffentlichungen allgemein
MECANISMOS RESISTENCIA IBRAF/MEK
www.groupgem.es
Paolo A Ascierto*, Dirk Schadendorf*, Carola Berking, Sanjiv S Agarwala, Carla M L van Herpen, Paola Queirolo, Christian U Blank, Axel Hauschild,. J Thaddeus Beck, Annie St-Pierre, Faiz Niazi, Simon Wandel, Malte Peters, Angela Zubel, Reinhard Dummer. Summary our patients and. 71 patients had.
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor...
www.pubfacts.com
PubFacts seeks to make the world's scientific research easy to locate, access, and collaborate on.
MEK162 for patients with advanced melanoma harbouring NRAS or Val
www.wikidata.org
scientific article
Artikel & Meinungen
Phase 2 Study of Cetuximab/Cisplatin vs Cisplatin - TNBC Foundation...
forum.tnbcfoundation.org
Randomized Phase II Study of the AntiEpidermal Growth Factor Receptor Monoclonal Antibody Cetuximab...
Sonstiges
Angela Zubel | LinkedIn
www.linkedin.com
largest business network, helping professionals like Angela Zubel discover
inside ...
Roma 22 Settembre La terapia medica del melanoma metastatico -...
slideplayer.com
Metastatic Melanoma: medical treatments Chemotherapy Single agent or poly-Chemotherapy monochemotherapy best option of care Immunotherapy : alpha IFNs, IL-2...
DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE Yahoo Finance
finance.yahoo.com
— " explained Angela Zubel, Chief Development Officer at Debiopharm. "We always have immense gratitude for our patients who participate in ...
Angela Zubel's research works | Lem Sa Switzerland, Fribourg and ...www.researchgate.net › _Angela_Zubel
www.researchgate.net
Angela Zubel's 12 research works with 167 citations and 424 reads, including: Debio and high-dose cisplatin chemoradiotherapy in high-risk ...
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line...
slideplayer.com
... Carlos Garcia Girón, Oksana Tarasova, Angela Zubel, Yaroslav Shparyk *University Medical Center Hamburg-EppendorfHamburg, ...
DEBIOPHARM SHARES ONCOLOGY PROGRAM ...Yahoo Finance
finance.yahoo.com
— Angela Zubel, Chief Development Officer at Debiopharm. ASCO Session Details. Title. Presenter. Poster Display: June 3rd 08: :00.
Angela Zubel Public Data
xlek.com
Angela Zubel. From: Blue Island, IL. Location: Artesian Ave,Blue Island, IL We found results for Angela Zubel in Marketing Data. We found 0 results for Angela Zubel in Public Property Records. We found results for Angela Zubel in Vehicle Sales Records. We found 0 results for Angela Zubel in Business ...
Randomized Phase III Trial of Cetuximab Plus Irinotecan vs Irinotecan...
slideplayer.com
CETUXIMAB : Clinical Development Program 3 3 rd line and beyond BOND, NCIC C nd line EPIC 1 st line CRYSTAL Adjuvant PETACC 8, NCCTG N0147
Angela Zubel - Debiopharm International SAMarketScreener
www.marketscreener.com
Currently, Angela Zubel occupies the position of Chief Development Officer & Director at Debiopharm International SA.
Angela Zubel - Director at NovadiscoveryThe Org
theorg.com
View Angela Zubel at Novadiscovery on The Org.
Angela Zubel, lekarz Kraków
med24.pl
Kontakt, email, www i dojazd do Angela Zubel, lekarz oferującej usługi z zakresu Ginekolog, Lekarze
Opinie o Angela Zubel, lekarz
badaniamedyczne.pl
Zobacz opinie i sprawdź rankinkg Angela Zubel, lekarz oferującej usługi z zakresu Ginekolog, Lekarze
Angela Zubel : Postes, Relations & RéseauZonebourse
www.zonebourse.com
Chief Tech/Sci/R&D Officer chez Debiopharm International SA, Découvrez l'historique des postes connus de Angela Zubel, le réseau et les 12 relations de ...
Opinie o Angela Zubel, lekarz - Ginekolog, Kraków lekarz
najlepszylekarz.pl
Zobacz opinie i sprawdź rankinkg Angela Zubel, lekarz
Angela Zubel : banen, relaties en netwerkMarketScreener
be.marketscreener.com
Currently, Angela Zubel occupies the position of Chief Development Officer & Director at Debiopharm International SA. Actieve functies van Angela Zubel ...
Angela Zubel's lab - DebiopharmResearchGate
www.researchgate.net
Principal Investigator: Angela Zubel | ResearchGate, the professional network for scientists.
Lek. Angela Zubel polecany Ginekolog KrakówABC Zdrowie
ranking.abczdrowie.pl
Lek. Angela Zubel – polecany przez użytkowników, bardzo dobry Ginekolog przyjmujący w mieście Kraków - rezerwuj wizytę na abczdrowie.pl.
Angela Zubel | CiNii ResearchCiNii Research
cir.nii.ac.jp
Angela Zubel · About this person · Related Articles · Related Data · Related Books · Related Dissertations · Related Projects · Related Products · Details.
Researcher: Angela Zubel in Publications - Dimensions
app.dimensions.ai
Re-imagining discovery and access to research: grants, datasets, publications, citations, clinical trials, patents and policy documents in one place.
Sigma-Aldrich
www.sigmaaldrich.com
Angela Zubel et al. Gynecologic oncology, 114(2), ( ). ADAM9 is a member of the ADAM family which is involved in cellular processes like ...
sortiert nach Relevanz / Datum